Hemophilia Treatment and Research
Hemophilia Treatment and Research is a research topic within Hematology. Science Explorer counts 19k research works in it since 1950. 12.4% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the management and treatment of hemophilia, including prophylaxis, inhibitors, gene therapy, and the impact on joint health. It covers a wide range of topics such as recombinant factor VIII, factor IX, and the safety and efficacy of various treatment strategies.
- Hemophilia
- Factor VIII
- Prophylaxis
- Inhibitors
- Recombinant Factor VIIa
- Gene Therapy
- Joint Disease
- Coagulation Disorders
- Efficacy
- Safety
- Research works
- 19k fractional, since 1950
- In the world top 10%
- 2.4k per year above
- Top-10% rate
- 12.4% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +23% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Hemophilia Treatment and Research research?
By volume, the United States and China publish the most (679 and 234 works in 2022–2025).
By volume, 2022–2025
- 1 United States 679 works
- 2 China 234 works
- 3 Germany 152 works
- 4 United Kingdom 146 works
- 5 India 144 works
- 6 Italy 140 works
- 7 Japan 139 works
- 8 Brazil 138 works
- 9 France 121 works
- 10 Spain 114 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Hemophilia Treatment and Research research?
By volume in 2022–2025, Hospital Universitario La Paz publishes the most Hemophilia Treatment and Research research, followed by Nara Medical University and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.
By volume, 2022–2025
- 1 Hospital Universitario La PazSpain 20 works
- 2 Nara Medical UniversityJapan 19 works
- 3 Fondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoItaly 18 works
- 4 Universidade Federal de Minas GeraisBrazil 16 works
- 5 Emory UniversityUnited States 16 works
- 6 University of North Carolina at Chapel HillUnited States 14 works
- 7 University Hospital BonnGermany 14 works
- 8 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 14 works
- 9 University of MilanItaly 13 works
- 10 McMaster UniversityCanada 13 works
Who are the leading researchers in Hemophilia Treatment and Research?
The most-cited researchers publishing on Hemophilia Treatment and Research include Gregory Y.H. Lip and LG Mantovani.
- 1 Gregory Y.H. Lip United Kingdom 2.7k citations
- 2 LG Mantovani Italy 2.3k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Hemophilia Treatment and Research research done?
The largest centres of Hemophilia Treatment and Research research in 2022–2025 are London (United Kingdom), Beijing (China), Madrid (Spain) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Bonn and Frankfurt am Main.
Largest cities, 2022–2025
- 1 London United Kingdom 54 works
- 2 Beijing China 51 works
- 3 Madrid Spain 45 works
- 4 Paris France 44 works
- 5 Milan Italy 40 works
- 6 New York United States 34 works
- 7 Tokyo Japan 33 works
- 8 Belo Horizonte Brazil 31 works
- 9 Philadelphia United States 26 works
- 10 Atlanta United States 26 works
Where it is the local speciality
- BonnDE · 22.4 works10×
- Frankfurt am MainDE · 20.7 works8.5×
Location quotient: how much more of its research is in Hemophilia Treatment and Research than the world average.
Where is the best place to study Hemophilia Treatment and Research?
Among universities, judged by research, Medical University of Vienna, University of Milan and Nara Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Medical University of ViennaAustria | 71.3 | 29.6% | 13.6× | 12 | +2.1% |
| 2 | University of MilanItaly | 63.4 | 30.3% | 7.0× | 13 | +11.0% |
| 3 | Nara Medical UniversityJapan | 60.4 | 11.2% | 100.4× | 19 | +38.1% |
| 4 | Goethe University FrankfurtGermany | 54.4 | 21.0% | 9.5× | 11 | -55.7% |
| 5 | McMaster UniversityCanada | 53.6 | 17.9% | 8.3× | 12 | -3.9% |
| 6 | University of BonnGermany | 50.0 | 23.9% | 8.4× | 8 | -19.3% |
| 7 | Universidade Estadual de Campinas (UNICAMP)Brazil | 49.9 | 21.0% | 5.2× | 12 | +118.2% |
| 8 | Emory UniversityUnited States | 47.9 | 9.7% | 7.8× | 16 | +28.5% |
| 9 | Universidade Federal de Minas GeraisBrazil | 40.7 | 4.2% | 7.4× | 16 | +22.8% |
| 10 | University College LondonUnited Kingdom | 40.6 | 23.4% | 2.6× | 10 | +29.1% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Hemophilia Treatment and Research research growing?
Output in 2018–2022 was 23% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Hemophilia Treatment and Research.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.